Wuxi AppTec Co's EPS (Basic) for the
three
months ended in Dec. 2023 was ¥0.52.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was ¥3.27.
During the past 12 months, Wuxi AppTec Co's average EPS without NRIGrowth Rate was 17.90% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 57.70% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 44.40% per year.
During the past 10 years, Wuxi AppTec Co's highest 3-Year average EPS without NRI Growth Rate was 59.50% per year. The lowest was 11.30% per year. And the median was 41.20% per year.
Wuxi AppTec Co Earnings per Share (Diluted) Historical Data
The historical data trend for Wuxi AppTec Co's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Wuxi AppTec Co's Earnings per Share (Diluted)
For the Diagnostics & Research subindustry, Wuxi AppTec Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuxi AppTec Co's PE Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Wuxi AppTec Co's PE Ratio distribution charts can be found below:
* The bar in red indicates where Wuxi AppTec Co's PE Ratio falls into.
Wuxi AppTec Co Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Wuxi AppTec Co's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥3.24
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
Wuxi AppTec Co (SHSE:603259) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Wuxi AppTec Co Earnings per Share (Diluted) Related Terms
Thank you for viewing the detailed overview of Wuxi AppTec Co's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services through the discovery, development, and manufacturing spectrum for small-molecule drugs, cell therapies, and gene therapies as well as providing testing services for medical devices. Its segments comprise China-based laboratory services; U.S.-based laboratory services; Clinical research and other CRO services; CDMO services; and Others. The majority of revenue gets derived from China-based laboratory services that include small molecules discovery, such as synthetic chemistry, medicinal chemistry, analytical chemistry, biology, drug metabolism and pharmacokinetics (DMPK)/absorption, distribution, metabolism, and excretion (ADME), toxicology and bioanalytical services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SHSE:603259 has been successfully added to your 